60,000 GALT shares @ $3.19 ave. cost per share. In deep for the big pay off when the results on patented GR-MD-02 weigh in on many peoples health, worldwide. This is a great buying opportunity and you "shorts" and "bashers" will be outsmarted by true investors.
Today's Financial Results & Product news UPDATE seems to have been favorably received by investors, which is probably the reason for today's volume & share price increase.
GALT may be a compelling opportunity. Im not sure about you guys but awe-som_sto-cks has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
Having followed GALT for the last 17 years, when it was Pro-Pharmaceutical, I'm NOT holding my breath waiting for the highly anticipated 2017 trial data. I doubt any investor can claim anything other than LOSSES in the speculation on GALT stock.
Come Dec 2017, I expect the same things as the trial data from their Sep 2016 when GALT told us "wait til next year, that'll be our year"
This will be back up to $3.00 a share end of November. GALT is a gamble, but it could pay off big.
China Education Resources CHN V
Great time to get into GALT at this price; was at $3 and change not that long ago. will definitely ramp up toward the $3 as we get closer to HUGE announcement at year-end.
$BLCM is another biotech scam like $CARA $AUPH $SGMO $ZYNE $CNAT $DCTH $GALT $CALA
+131pct in intraday gainz on their last NASDAQ Plck --> PennySt0ck101.org
GALT looking good with good volumes. Looks like a reversal is coming.
So what's happening here? Same old pump and dump as we've seen many times before or something actually going on?
$CARA $ZYNE $SGMO $CNAT $AUPH $GALT $CALA $AVEO $DCTH these guys are biotech scams. Longs can wake up to massive losses at any day. Like $ZYNE losses 55%today.
Galts patented GR-MD-02 popularity is on the rise again with todays major announcement. Galt was awarded another patent to protect the enormous demand that this drug will bring to the medical community. Big pharma is paying close attention...
summer blues here at GALT. How low can we go til we get to December? No buyers and I bet management is selling shares any chance they get through the damn ATM. Holding tight though, would hate to be out if they strike a deal. this sucks but thinking of the Tobira deal keeps me hanging on.
KTOV = Mcap $16 Mil /Cash $17 Mil /Low float O/S 10 M / NDA submission for Big Drug this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys
Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.
KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously
Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial
Marketing potential Pipeline candidates address large, multi-billion dollar markets
“KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”
Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.
Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics
NORCROSS, Ga., June 21, 2017-- Galectin Therapeutics, Inc., the leading developer of therapeutics that target galectin proteins, today announced that the Company has received notice of allowance for a ...
Galectin Therapeutics Inc. (GALT) Rating Increased to Buy at Zacks Investment Research
Galectin Therapeutics Inc. (NASDAQ:GALT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday, June 13th. The firm currently has a $2.75 target price on the stock. Zacks Investment Re